Essential thrombocytosis screening: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| (3 intermediate revisions by the same user not shown) | |||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Screening for essential thrombocytosis by cell-based quantitative assays for ''[[JAK2|JAK2V617F]]'' mutation is recommended among patients with [[thrombocytosis]], [[erythrocytosis]], and [[monocytosis]].<ref name="The Asco Post">The Asco Post. JAK2 and MPL Mutation Screening: What Are the Indications and How to Interpret the Results. http://www.ascopost.com/issues/february-15-2012/jak2-and-mpl-mutation-screening-what-are-the-indications-and-how-to-interpret-the-results.aspx</ref><ref name="pmid21723416">{{cite journal| author=Tefferi A, Noel P, Hanson CA| title=Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology. | journal=J Mol Diagn | year= 2011 | volume= 13 | issue= 5 | pages= 461-6 | pmid=21723416 | doi=10.1016/j.jmoldx.2011.05.007 | pmc=PMC3157620 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21723416 }} </ref> | Screening for essential thrombocytosis by cell-based quantitative assays for ''[[JAK2|JAK2V617F]]'' mutation is recommended among individuals with a positive family history for the disease (autosomal dominant inheritance) and in patients who present with [[thrombocytosis]], [[erythrocytosis]], and [[monocytosis]].<ref name="The Asco Post">The Asco Post. JAK2 and MPL Mutation Screening: What Are the Indications and How to Interpret the Results. http://www.ascopost.com/issues/february-15-2012/jak2-and-mpl-mutation-screening-what-are-the-indications-and-how-to-interpret-the-results.aspx</ref><ref name="pmid21723416">{{cite journal| author=Tefferi A, Noel P, Hanson CA| title=Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology. | journal=J Mol Diagn | year= 2011 | volume= 13 | issue= 5 | pages= 461-6 | pmid=21723416 | doi=10.1016/j.jmoldx.2011.05.007 | pmc=PMC3157620 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21723416 }} </ref> | ||
==Screening== | ==Screening== | ||
Screening for essential thrombocytosis by cell-based quantitative assays for ''[[JAK2|JAK2V617F]]'' mutation is recommended among the following:<ref name="The Asco Post">The Asco Post. JAK2 and MPL Mutation Screening: What Are the Indications and How to Interpret the Results. http://www.ascopost.com/issues/february-15-2012/jak2-and-mpl-mutation-screening-what-are-the-indications-and-how-to-interpret-the-results.aspx</ref><ref name="pmid21723416">{{cite journal| author=Tefferi A, Noel P, Hanson CA| title=Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology. | journal=J Mol Diagn | year= 2011 | volume= 13 | issue= 5 | pages= 461-6 | pmid=21723416 | doi=10.1016/j.jmoldx.2011.05.007 | pmc=PMC3157620 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21723416 }} </ref> | |||
* | *Individuals with a family history of essential thrombocytosis ([[autosomal dominant]] inheritance) | ||
* | *Patients who present with [[thrombocytosis]], [[erythrocytosis]], and [[monocytosis]]. | ||
==References== | ==References== | ||
Latest revision as of 15:52, 5 January 2016
|
Essential thrombocytosis Microchapters |
|
Differentiating Essential thrombocytosis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Essential thrombocytosis screening On the Web |
|
American Roentgen Ray Society Images of Essential thrombocytosis screening |
|
Risk calculators and risk factors for Essential thrombocytosis screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Soujanya Thummathati, MBBS [2]
Overview
Screening for essential thrombocytosis by cell-based quantitative assays for JAK2V617F mutation is recommended among individuals with a positive family history for the disease (autosomal dominant inheritance) and in patients who present with thrombocytosis, erythrocytosis, and monocytosis.[1][2]
Screening
Screening for essential thrombocytosis by cell-based quantitative assays for JAK2V617F mutation is recommended among the following:[1][2]
- Individuals with a family history of essential thrombocytosis (autosomal dominant inheritance)
- Patients who present with thrombocytosis, erythrocytosis, and monocytosis.
References
- ↑ 1.0 1.1 The Asco Post. JAK2 and MPL Mutation Screening: What Are the Indications and How to Interpret the Results. http://www.ascopost.com/issues/february-15-2012/jak2-and-mpl-mutation-screening-what-are-the-indications-and-how-to-interpret-the-results.aspx
- ↑ 2.0 2.1 Tefferi A, Noel P, Hanson CA (2011). "Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology". J Mol Diagn. 13 (5): 461–6. doi:10.1016/j.jmoldx.2011.05.007. PMC 3157620. PMID 21723416.